- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03177681
The Effect of Yogurt in Cancer Patient With Moderate Gastrointestinal (GI) Symptoms
Study Overview
Status
Intervention / Treatment
Detailed Description
Baseline Tests:
If you agree to take part in this study, you will have the following tests and procedures when you enroll:
- The coating on your tongue will be checked. Researchers think that the thickness of the coating on your tongue may be related to the microorganisms in your stomach and/or intestines.
- A stool sample will be collected for bacteria testing.
- You will be asked about your diet and how often you eat yogurt.
- You will wear a monitoring device called a Holter monitor for 20-24 hours to check your nervous system and heart function.
- You will be asked to complete 4 questionnaires about your symptoms in the past 24 hours, your irritable bowel syndrome (IBS), your most recent stool, and your quality-of-life. These questionnaires should take about 30 minutes total to complete.
Study Procedures:
One (1) time during Days 3-7 and 1 time during Days 8-12:
- You will be asked to complete the same 4 questionnaires you completed at baseline.
- A stool sample will be collected by your bedside nurse for bacteria testing.
- You may wear a Holter monitor to check your heart function.
You will be given at least 2 tablespoons (33 cc) of DannonÒ OikosÒyogurt each day.
Length of Study:
Your participation in this study will be over after you complete the study procedures during Days 8 to 12.
If you are discharged before you complete the study procedures above, you will be called and asked about your symptoms and given a stool collection kit. This phone call should take about 30 minutes to complete. The study staff will give you more information about stool collection. Your sample will be collected for bacteria testing at your next clinic visit.
This is an investigational study. The use of probiotics in yogurt to treat GI symptoms in cancer patients is investigational. The study doctor can explain how the probiotics are designed to work.
Up to 40 participants will be enrolled in this study. All will take part at MD Anderson.
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- University of Texas MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Cancer patient
- 18 years old or older
- Has gastrointestinal symptoms with severity score of </= 60 out of 100 visual analog scale for irritable bowel syndrome (VAS-IBS) in at least 2 out of 7 items measured
- Able to eat by mouth
- Estimated length of hospital stay is 10 days or more
- Must give written study consent
Exclusion Criteria:
- Neutropenic patient with absolute neutrophil count (ANC) less than 1000 cells/mm3
- Patient within 100 days of auto /allo stem cell transplant and their stem cell physician does not approve yogurt ingestion.
- Has intestinal obstruction.
- Patient is currently on antibiotics
- Allergic to yogurt
- Patient who eats yogurt equal or more than once a day in the last 3 days.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Group 1 - Antibiotics Taken During Past 2 Weeks
Group 1: Participant was on antibiotics anytime during the past 2 weeks prior to the time of enrollment. Tongue assessment, stool sample, and questionnaires done at baseline and once during Days 3-7 and once during Days 8-12. Participants wear a Holter monitor for 20-24 hours at baseline and once during Days 3-7 and once during Days 8-12. Participants given 2 tablespoons (33 cc) of yogurt each day for 12 days. |
The coating on the top of the tongue assessed and categorized into three categories: no coating, thin coating and thick coating.
The coating of the tongue may be related to the microorganisms in the intestine.
Stool sample collected at baseline and once during Days 3-7 and once during Days 8-12.
Participants complete 4 questionnaires about symptoms in the past 24 hours, irritable bowel syndrome (IBS), most recent stool, and quality-of-life.
Questionnaires completed at baseline and once during Days 3-7 and once during Days 8-12.
Questionnaires should take about 30 minutes total to complete.
Other Names:
Participants wear a Holter monitor for 20-24 hours to check nervous system and heart function at baseline and once during Days 3-7 and once during Days 8-12.
Participants given 2 tablespoons (33 cc) of DannonÒ OikosÒ yogurt each day for 12 days.
|
|
Experimental: Group 2 - No Antibiotics Taken During Past 2 Weeks
Group 2: Participant has not been on antibiotics in the past 2 weeks. Tongue assessment, stool sample, and questionnaires done at baseline and once during Days 3-7 and once during Days 8-12. Participants wear a Holter monitor for 20-24 hours at baseline and once during Days 3-7 and once during Days 8-12. Participants given 2 tablespoons (33 cc) of yogurt each day for 12 days. |
The coating on the top of the tongue assessed and categorized into three categories: no coating, thin coating and thick coating.
The coating of the tongue may be related to the microorganisms in the intestine.
Stool sample collected at baseline and once during Days 3-7 and once during Days 8-12.
Participants complete 4 questionnaires about symptoms in the past 24 hours, irritable bowel syndrome (IBS), most recent stool, and quality-of-life.
Questionnaires completed at baseline and once during Days 3-7 and once during Days 8-12.
Questionnaires should take about 30 minutes total to complete.
Other Names:
Participants wear a Holter monitor for 20-24 hours to check nervous system and heart function at baseline and once during Days 3-7 and once during Days 8-12.
Participants given 2 tablespoons (33 cc) of DannonÒ OikosÒ yogurt each day for 12 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage Change in Bacteroidetes in Stool from Baseline to Day 12
Time Frame: Baseline to Day 12
|
Baseline to Day 12
|
|
Percentage Change in Firmicutes in Stool from Baseline to Day 12
Time Frame: Baseline to Day 12
|
Baseline to Day 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adherence Rate of Dannon® Oikos® Yogurt Intake
Time Frame: 12 days
|
Adherence rate calculated as percentage of times that a participant takes at least 2 table spoon (30 cc) of yogurt/day consumed for the 10±2 day prescription, as well as for the first 5±2 days, and will be summarized for each group using descriptive statistics.
Regimen considered feasible for each group if at least 70% of participants in that group have reached at least 70% adherence rate in 10±2 days.
|
12 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: An T. Ngo-Huang, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017-0052
- NCI-2018-01356 (Registry Identifier: NCI CTRP)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Neoplasms of Independent (Primary) Multiple Sites
-
M.D. Anderson Cancer CenterWithdrawnMalignant Neoplasms of Independent (Primary) Multiple Sites
-
M.D. Anderson Cancer CenterActive, not recruitingMalignant Neoplasms of Independent (Primary) Multiple Sites | Benign NeoplasmsUnited States
-
M.D. Anderson Cancer CenterCompletedAdvanced Cancer | Malignant Neoplasms of Independent (Primary) Multiple SitesUnited States
-
M.D. Anderson Cancer CenterCompletedMalignant Neoplasms of Independent (Primary) Multiple SitesUnited States
-
M.D. Anderson Cancer CenterCompletedMalignant Neoplasms of Independent (Primary) Multiple Sites | Benign Neoplasms | In Situ NeoplasmsUnited States
-
M.D. Anderson Cancer CenterCompletedMalignant Neoplasms of Independent (Primary) Multiple SitesUnited States
-
M.D. Anderson Cancer CenterCompletedMalignant Neoplasms of Independent (Primary) Multiple SitesUnited States
-
M.D. Anderson Cancer CenterMerck Sharp & Dohme LLC; BioMed Valley Discoveries, IncActive, not recruitingMalignant Neoplasms of Female Genital Organs | Malignant Neoplasm of Breast | Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites | Malignant Neoplasms of Lip Oral Cavity and Pharynx | Malignant Neoplasms of Independent (Primary) Multiple Sites | Malignant Neoplasms of Mesothelial... and other conditionsUnited States
-
M.D. Anderson Cancer CenterEisai Inc.WithdrawnAdvanced Cancer | Malignant Neoplasms of Female Genital Organs | Malignant Neoplasm of Breast | Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites | Malignant Neoplasms of Lip Oral Cavity and Pharynx | Malignant Neoplasms of Independent (Primary) Multiple Sites | Malignant Neoplasms... and other conditions
-
M.D. Anderson Cancer CenterGateway for Cancer Research; James B. and Lois R. Archer Charitable FoundationRecruitingMalignant Neoplasms of Female Genital Organs | Malignant Neoplasms of Lip Oral Cavity and Pharynx | Melanoma and Other Malignant Neoplasms of Skin | Malignant Neoplasm of Bone and Articular Cartilage | Malignant Neoplasms of Independent (Primary) Multiple Sites | Malignant Neoplasm of Male... and other conditionsUnited States
Clinical Trials on Tongue Assessment
-
Université Catholique de LouvainRecruiting
-
Université Catholique de LouvainCompleted
-
Chang Gung Medical FoundationTaipei Medical UniversityCompletedDysphagia, OropharyngealTaiwan
-
Siesta Medical, Inc.Terminated
-
Georgia Institute of TechnologyNorthwestern University; University of Arizona; Shirley Ryan AbilityLab; Shepherd...CompletedALS | Spinal Cord Injury | QuadriplegiaUnited States
-
First Affiliated Hospital of Wenzhou Medical UniversityCompletedLiver Diseases | Small Bowel Disease | Colorectal Disease | Gastric Diseases | Digestive Tract DiseasesChina
-
Sleepy, IncTerminatedSnoring | Obstructive Sleep ApneaAustralia, United States
-
University of South FloridaTexas Christian University; Loma Linda University; James Madison UniversityUnknown
-
Shahid Beheshti University of Medical SciencesCompletedMaxillary DeficiencyIran, Islamic Republic of
-
Universitaire Ziekenhuizen KU LeuvenRecruitingPeriodontitis | Halitosis | Tongue ConditionBelgium